Karvedilol Viatris

Carvedilol, the active ingredient in Karvedilol, is a non‑selective β‑adrenergic antagonist with α1‑adrenergic blocking activity presented as an oral tablet for oral use. It is indicated for hypertension, chronic heart failure, and left ventricular dysfunction following myocardial infarction in adult patients.

GNH USA supplies Karvedilol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from GNH USA's expertise in regulatory compliance and customs clearance across multiple regions.

Carvedilol is used to manage several cardiovascular conditions by reducing blood pressure, decreasing heart rate, and improving cardiac output, which together help control disease progression. - Hypertension: lowers systemic blood pressure, reducing risk of stroke, myocardial infarction, and other cardiovascular events. - Chronic heart failure: improves left ventricular ejection fraction, reduces symptoms of dyspnea, and decreases hospitalization rates. - Left ventricular dysfunction after myocardial infarction: enhances cardiac remodeling, improves functional capacity, and supports long‑term survival outcomes. - Overall mortality: contributes to reduced all‑cause mortality in patients with hypertension and heart failure.

Carvedilol may be associated with a range of adverse reactions, varying from mild to serious. Common Side Effects: - Dizziness or light‑headedness - Fatigue or tiredness - Headache - Peripheral edema Serious or Rare Side Effects: - Severe bradycardia or heart block - Acute bronchospasm in patients with asthma or COPD - Hepatic dysfunction or jaundice

When prescribing Carvedilol, clinicians should consider several precautionary measures to ensure patient safety. - Cardiovascular monitoring: assess heart rate and blood pressure regularly, especially during dose titration. - Respiratory caution: avoid use in patients with uncontrolled asthma or severe chronic obstructive pulmonary disease. - Diabetes management: monitor blood glucose as β‑blockade may mask hypoglycaemic symptoms. - Hepatic impairment: adjust dosing or avoid in severe liver disease due to altered metabolism. - Concomitant anti‑arrhythmic therapy: evaluate for additive effects on cardiac conduction. - Store below 25°C: keep in the original pack, protect from moisture.

Carvedilol can interact with other medicines, influencing its efficacy or safety profile. Major Interactions (Avoid): - Non‑selective β‑blockers: combined use may cause excessive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): increase risk of heart block and reduced cardiac output. - Strong CYP2D6 inhibitors (e.g., quinidine, paroxetine): raise carvedilol plasma levels, enhancing adverse effects. Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypotensive effect, requiring blood pressure monitoring. - Antidiabetic agents: β‑blockade can mask hypoglycaemia, adjust glucose monitoring. - NSAIDs: may diminish antihypertensive efficacy, monitor blood pressure.